1.
Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. Swiss Med Wkly [Internet]. 2008 Jul. 26 [cited 2025 Nov. 4];138(2930):420-6. Available from:
https://smw.ch/index.php/smw/article/view/876